Valuation : Gennex Laboratories Limited

Market Cap 1.73B 18.35M 15.79M 14.85M 13.57M 25.38M 25.45M 176M 68.11M 889M 68.89M 67.39M 2.86B P/E 2024
26x
P/E 2025 15.4x
Enterprise Value 1.46B 15.44M 13.28M 12.5M 11.42M 21.36M 21.41M 148M 57.31M 748M 57.97M 56.7M 2.41B EV / Sales 2024
3.67x
EV / Sales 2025 1.79x
Free-Float
63.52%
Yield 2024 *
-
Yield 2025 -
08-14 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
05-30 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-14 Gennex Laboratories Limited Resignation of Shilpa Bung, Non-Executive Independent Women Director, Effective February 14, 2026 CI
02-14 Gennex Laboratories Limited Appoints Khushbu Kachhawa as Additional Director (Non-Executive Independent Women Director) CI
02-14 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
11-14 Gennex Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
14/08/25 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
30/05/25 Gennex Laboratories Limited Announces Resignation of Dr. Sch Dharma Rao as Non-Executive Non-Independent Director, Effective May 30, 2025 CI
30/05/25 Gennex Laboratories Limited Appoints Sandeep Kumar Daga as Non-Executive Non-Independent Director CI
30/05/25 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
14/02/25 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
14/02/25 Gennex Laboratories Limited Announces Resignation of Mohammed Khaleequr Rahman as Non-Executive Non-Independent Director CI
14/11/24 Gennex Laboratories Limited Approves the Appointment of Akkali Santosh Kumar as Chief Financial Officer CI
1 day+2.71%
1 week-6.12%
Current month-3.96%
1 month+36.18%
3 months+14.12%
6 months+8.02%
Current year-15.24%
1 week 11.7
Extreme 11.7
12.99
1 month 8.75
Extreme 8.75
13.25
Current year 7.05
Extreme 7.05
14.77
1 year 7.05
Extreme 7.05
17.25
3 years 7.05
Extreme 7.05
29
5 years 4.81
Extreme 4.81
29
10 years 1.32
Extreme 1.32
29
Manager TitleAgeSince
Chief Executive Officer 40 17/05/2012
Director of Finance/CFO - 11/11/2024
Compliance Officer 62 19/04/2023
Director TitleAgeSince
Chairman 40 -
Director/Board Member - 20/12/2020
Director/Board Member - 20/12/2020
Change 5-day change 1-year change 3-year change Capi.($)
+2.71%-6.12%+6.78%+51.31% 31.19M
-0.88%-2.15%+58.05%+105.91% 1,024B
-1.15%+2.68%+54.25%+71.29% 663B
-1.44%+0.38%+20.65%+75.54% 453B
+0.14%-0.47%+30.20%+40.61% 352B
-1.33%+4.72%+24.62%+47.60% 304B
-1.15%+0.30%-0.69%+11.83% 252B
-1.55%+1.11%+54.15%+72.13% 236B
-0.88%+1.15%-14.60%-54.84% 206B
-0.15%+3.65%+31.24%+100.90% 187B
Average -0.57%+0.37%+26.47%+52.23% 367.84B
Weighted average by Cap. -0.96%+0.55%+37.63%+67.00%

Financials

2024 2025
Net sales 867M 9.18M 7.9M 7.44M 6.79M 12.71M 12.74M 87.87M 34.1M 445M 34.49M 33.74M 1.43B 1.38B 14.61M 12.57M 11.83M 10.8M 20.21M 20.26M 140M 54.22M 708M 54.85M 53.65M 2.28B
Net income 132M 1.4M 1.2M 1.13M 1.03M 1.93M 1.94M 13.35M 5.18M 67.6M 5.24M 5.13M 218M 181M 1.92M 1.65M 1.55M 1.42M 2.66M 2.66M 18.36M 7.13M 92.98M 7.21M 7.05M 300M
Net Debt -413M -4.37M -3.76M -3.54M -3.23M -6.05M -6.07M -41.84M -16.24M -212M -16.42M -16.07M -683M -275M -2.91M -2.5M -2.36M -2.15M -4.03M -4.04M -27.84M -10.8M -141M -10.93M -10.69M -454M
Logo Gennex Laboratories Limited
Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing of bulk drugs and intermediaries. It offers products in various therapeutic categories, including expectorant (mucolyte), relaxant (skeletal muscle relaxant), antihistamines, urinary tract analgesic, antifungals called triazoles, tricyclic antidepressant, acting muscle relaxants, muscle relaxant, selective serotonin reuptake inhibitors (SSRIS), and xanthine oxidase inhibitors. Its products include Guaifenesin, Methocarbamol, Fexofenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl and Allopurinol. The Company has manufacturing facilities in India which cater to both domestic and international markets. Its international markets include Bangladesh, Bolivia, China, Colombia, Costa Rica, Cuba, Germany, Indonesia, Iran, Iraq, Israel, Jordan, Kenya, South Korea, Malaysia and Mexico.
Employees
115
Date Price Change Volume
04/09/26 ₹12.12 +2.71% 320,497
03/09/26 ₹11.80 -1.99% 283,127
02/09/26 ₹12.04 -0.50% 535,384
01/09/26 ₹12.10 -4.12% 658,584
31/08/26 ₹12.62 -2.25% 491,430
  1. Stock Market
  2. Stocks
  3. GENNEX6 Stock